GlassScriptPhysician profile
Lonnie Mark Hammonds
NPI 1356464838
$4,295.87
in general payments reported to CMS, 2019-2025
20 companies · $539 in 2025
The $539 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $774 · 2020: $744 · 2021: $633 · 2022: $765 · 2023: $407 · 2024: $433 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,379.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,098.72 | 2019-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $679.67 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $515.63 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $418.39 | 2019-2025 | Odomzo, Blu-U |
| Genzyme Corporation | $369.93 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $252.03 | 2019-2023 | Dupixent |
| Abbvie INC. | $194.16 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $191.94 | 2019-2025 | |
| Ucb, INC. | $145.97 | 2019-2025 | Bimzelx |
| Vyne Pharmaceuticals INC. | $105.76 | 2020-2021 | |
| Dusa Pharmaceuticals, INC. | $90.72 | 2019 | |
| Pfizer INC. | $49.68 | 2019-2022 | |
| Genentech USA, INC. | $45.82 | 2021-2023 | Xolair |
| Janssen Scientific Affairs, LLC | $25.39 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.88 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $22.52 | 2025 | Adbry |
| Celgene Corporation | $19.24 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.06 | 2022 | |
| Dermavant Sciences, INC. | $14.54 | 2023 | Vtama |
| Galderma Laboratories, L.P. | $13.82 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lonnie Hammonds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.